Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

Genomic Analysis of Hodgkin Lymphoma

Ralf Küppers, PhD

Blood (2019) 134 (Supplement_1): SCI-7.

https://doi.org/10.1182/blood-2019-121073

Published: 2019

Journal Articles

Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study

Leo Meriranta, MD, Amjad Alkodsi, PhD, Annika Pasanen, MD PhD, Maija Lepistö, MSc, Yngvild Nuvin Blaker, MD PhD, Matias Autio, Judit Jørgensen, MD PhD, Mats Jerkeman, MD Professor, Harald Holte, MD PhD, Pekka Ellonen, BSc, Sirpa Leppa, MD Prof

Blood (2019) 134 (Supplement_1): 1481.

https://doi.org/10.1182/blood-2019-132168

Published: 2019

Journal Articles

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Ryan N Rys, BSc, BA, Dominique Geoffrion, BSc, Christopher Rushton, BSc, Miguel Alcaide, PhD, Raoul Santiago, MDMSc, Koren Kathleen Mann, PhD, Svetlana Dmitrienko, MD PhD, Tina Petrogiannis-Haliotis, MD PhD, Sarit Assouline, MD, Ryan D. Morin, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1608.

https://doi.org/10.1182/blood-2019-127129

Published: 2019

Journal Articles

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1424.

https://doi.org/10.1182/blood-2019-122890

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Jason R. Westin, MD, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Hun Ju Lee, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Raphael E Steiner, MD, Sairah Ahmed, MD, Simrit Parmar, MBBS, Ranjit Nair, MBBS,MD, Rebecca Harrison, MD, Luis Fayad, MD

Blood (2019) 134 (Supplement_1): 4086.

https://doi.org/10.1182/blood-2019-131463

Published: 2019

Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD

Blood (2019) 134 (Supplement_1): 4031.

https://doi.org/10.1182/blood-2019-125385

Published: 2019

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 2877.

https://doi.org/10.1182/blood-2019-128021

Published: 2019

Journal Articles

Trasposon Mediated Horizontal Gene Transfer (T-HGT) of Circulating Tumor DNA Reshapes MM Clonal Architecture

Munevver Cinar, MD, Steven Flygare, Marina Mosunjac, Ganji Nagaraju, Dongkyoo Park, Sheff Faith, Debra Saxe, PhD, Leon Bernal-Mizrachi, MD

Blood (2019) 134 (Supplement_1): 3065.

https://doi.org/10.1182/blood-2019-126699

Published: 2019

Journal Articles

Molecular Characterization of Ph-Negative Myeloproliferative Neoplasms in Tumor Circulating Nucleic Acids

Nieves Garcia-Gisbert, MSc, Lierni Fernández-Ibarrondo, Concepción Fernández-Rodríguez, Laura Camacho, Anna Angona, MD PhD, Joan Gibert, PhD, Xavier Calvo, MD PhD, Leonor Arenillas, MD PhD, Raquel Longarón, Marcio Andrade, MD PhD, Antonio Salar, MD PhD, Carles Besses, MD PhD, Beatriz Bellosillo, PhD

Blood (2019) 134 (Supplement_1): 2953.

https://doi.org/10.1182/blood-2019-123003

Published: 2019

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

https://doi.org/10.1182/blood-2019-125990

Published: 2019

Journal Articles

Cnspectorx - Copy Number Assessment at a Genome Level from Targeted Sequence Data Optimized for Hematological Malignancy

John Markham, Satwica Yerneni, MS, Georgina L Ryland, Andrew Fellowes, PhD, Ella Thompson, PhD BSc, Stephen Fox, David Alan Westerman, MBBS, FRCPA, FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, Anthony Papenfuss, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 3378.

https://doi.org/10.1182/blood-2019-125471

Published: 2019

Journal Articles

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4350.

https://doi.org/10.1182/blood-2019-131037

Published: 2019

Journal Articles

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Stefan Alig, MD, Charles Macaulay, MSc, BA, David M. Kurtz, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Michael C. Jin, BS, Brian Sworder, MD PhD, Andrea Garofalo, BS, BA, Mohammad Shahrokh Esfahani, Joanne Soo, MD, Florian Scherer, MD, Alexander Craig, MPhil, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 491.

https://doi.org/10.1182/blood-2019-129283

Published: 2019

Journal Articles

A New Valuable Technique in Diagnosis and Treatment Monitoring of Myeloproliferative Neoplasms

Yiqian Hu, Sanyun Wu, Yanan Liu, Mengxiao Zhang, Yingying Wang, Liang Shao, Bei Xiong, Xiaoyan Liu, Yicheng Zhang, Rui Lu, Yalan Yu, Ping Luo, Xuelan Zuo

Blood (2019) 134 (Supplement_1): 5377.

https://doi.org/10.1182/blood-2019-128709

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Genomic Analysis of Hodgkin Lymphoma

Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

Trasposon Mediated Horizontal Gene Transfer (T-HGT) of Circulating Tumor DNA Reshapes MM Clonal Architecture

Molecular Characterization of Ph-Negative Myeloproliferative Neoplasms in Tumor Circulating Nucleic Acids

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Cnspectorx - Copy Number Assessment at a Genome Level from Targeted Sequence Data Optimized for Hematological Malignancy

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

A New Valuable Technique in Diagnosis and Treatment Monitoring of Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only